Glenmede Trust’s Verona Pharma VRNA Stock Holding History

Glenmede Trust’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$731K	Buy	11,517 +485	+4%	+$29K	﹤0.01%	790
2024 Q4	$512K	Sell	11,032 -19,219	-64%	-$722K	﹤0.01%	925
2024 Q3	$870K	Sell	30,251 -4,565	-13%	-$112K	﹤0.01%	757
2024 Q2	$503K	Buy	34,816 +370	+1%	+$5.4K	﹤0.01%	903
2024 Q1	$554K	Sell	34,446 -475	-1%	-$8.21K	﹤0.01%	900
2023 Q4	$694K	Sell	34,921 -4,084	-10%	-$60.3K	﹤0.01%	802
2023 Q3	$636K	Sell	39,005 -5,475	-12%	-$105K	﹤0.01%	771
2023 Q2	$893K	Hold	44,480	–	–	0.01%	689
2023 Q1	$893K	Buy	44,480 +16,175	+57%	+$349K	0.01%	691
2022 Q4	$740K	Sell	28,305 -1,910	-6%	-$25.4K	﹤0.01%	724
2022 Q3	$308K	Buy	+30,215	New	+$255K	﹤0.01%	949

Other funds holding VRNA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Glenmede Trust's VRNA Position: Q1 2025 in Review

Glenmede Trust increased its Verona Pharma (VRNA) stake by 4.4% in Q1 2025, buying an estimated $29K and bringing the position to 11,517 shares worth $731K. The position accounts for ﹤0.01% of the portfolio, ranked #790.

Glenmede Trust first reported a position in VRNA in Q3 2022 and has held it in 11 quarters since. The position peaked at $893K in Q2 2023. 258 funds tracked by Wall St. Rank hold VRNA as of Q1 2025.

Glenmede Trust held 11,517 shares of Verona Pharma worth $731K as of Q1 2025.
Glenmede Trust bought 485 Verona Pharma shares in Q1 2025, an estimated $29K.
Verona Pharma made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2025, its #790 holding.
Glenmede Trust first reported a position in Verona Pharma in Q3 2022 and has held it in 11 quarters since.
Glenmede Trust's Verona Pharma position peaked at $893K in Q2 2023.
258 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2025.

Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.